Related references
Note: Only part of the references are listed.First report of the emergence of CTX-M-Type extended-spectrum β-lactamases (ES-BLs) as the predominant ESBL isolated in a US health care Systemdel
James S. Lewis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory
Neil Woodford et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
CTX-M: changing the face of ESBLs in Europe
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Emergence of PER and VEB extended-spectrum β-lactamases in Acinetobacter baumannii in Belgium
Thierry Naas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
CTX-M: changing the face of ESBLs in the UK
DM Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Outbreak of Klebsiella pneumoniae producing a new carbapenern hydrolyzing class a β-lactamase, KPC-3, in a New York Medical Center
N Woodford et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City
PA Bradford et al.
CLINICAL INFECTIOUS DISEASES (2004)
Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat
PA Bradford
CLINICAL MICROBIOLOGY REVIEWS (2001)
Share Paper
